More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$9.44B
EPS
-2.78
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
3.248818
Previous close
$104
Today's open
$102.26
Day's range
$98.81 - $106.20
52 week range
$23.01 - $110.64
show more
CEO
Cameron Turtle
Employees
125
Headquarters
Waltham, MA
Exchange
Nasdaq Global Select
Shares outstanding
94969184
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Spyre Therapeutics, Inc. (SYRE) Presents at UBS Global Biopharma Conference 2026 Transcript
Spyre Therapeutics, Inc. (SYRE) Presents at UBS Global Biopharma Conference 2026 Transcript
Seeking Alpha • Nov 16, 2026

Spyre Therapeutics to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that management will participate in the following upcoming investor conferences in November and December: Event : UBS Global Biopharma Conference – London Date: Monday, November 16, 2026 Fireside Time: 1:20 pm GMT Event: Jefferies Global Healthcare Conference – London Date: Tuesday, November 17, 2026 Fireside Time: 3:00 pm GMT Event: 9th Annual Evercore Healthcare Conference - Miami Date: Tuesday, December 1, 2026 Fireside Time: 3:00 pm ET Event: Citi's 2026 Global Healthcare Conference - Miami Date: Wednesday, December 2, 2026 Fireside Time: 9:40 am ET Members of the Spyre management team will also host one-on-one investor meetings during the conferences.
GlobeNewsWire • Nov 10, 2026

Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 11,138 shares of common stock of Spyre and 3,195 restricted stock units (“RSUs”) to two non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options and RSUs were approved on November 2, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).
GlobeNewsWire • Nov 6, 2026

Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Announced positive topline induction data for SPY003 from Part A of the Phase 2 SKYLINE trial (“SKYLINE”), completing proof-of-concept for all three monotherapies in inflammatory bowel disease (“IBD”). SKYLINE Part B is enrolling ahead of schedule, enabling the Company to increase enrollment and provide topline induction results for three potential best-in-indication combinations, which are expected in Q3 2027
GlobeNewsWire • Nov 3, 2026

Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
WALTHAM, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced presentations at United European Gastroenterology Week (UEGW) 2026 in Barcelona. The presentations include the first scientific congress presentation of clinical data across all three of Spyre's IBD antibodies—SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23)—which are now being tested as monotherapies and pairwise combinations in the SKYLINE study, as well as new preclinical data demonstrating additive efficacy of these complementary mechanisms.
GlobeNewsWire • Oct 18, 2026

Spyre: Maintain 'Strong Buy' On Additional SPY072 Shots On Goal Q4 2026 And IBD Combination Potential
Spyre Therapeutics maintains a 'Strong Buy' rating, driven by promising IBD pipeline progress and robust cash reserves. SYRE's three monotherapy candidates—SPY001, SPY002, SPY003—show potential best-in-class efficacy for IBD, with combination data expected in 2027. Despite discontinuing SPY072 monotherapy for RA, SYRE retains upside via upcoming PsA, axSpA, and combination readouts in late 2026–2028.
Seeking Alpha • Oct 7, 2026

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that it has commenced an underwritten public offering of its common stock. In addition, the Company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase an additional 15% of the shares of common stock offered in the public offering under the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
GlobeNewsWire • Oct 5, 2026

Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced the pricing of its previously announced underwritten public offering of 4,117,648 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to the Company from this offering are expected to be approximately $350.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, the Company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional approximately $52.5 million of shares of the Company's common stock offered in the public offering under the same terms and conditions. The offering is expected to close on or about October 7, 2026, subject to satisfaction of customary closing conditions.
GlobeNewsWire • Oct 6, 2026

Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Seeking Alpha • Sep 9, 2026

Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study
SYRE's SPY003 posts positive phase II UC data, strengthening Spyre's multi-mechanism IBD strategy.
Zacks Investment Research • Sep 9, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Spyre Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.